Five Oceans Advisors Boosts Stake in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 26th, 2023

Five Oceans Advisors lifted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 33.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,017 shares of the biopharmaceutical company’s stock after purchasing an additional 2,483 shares during the quarter. Five Oceans Advisors’ holdings in Pfizer were worth $409,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Moneta Group Investment Advisors LLC boosted its position in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the period. Norges Bank purchased a new position in Pfizer during the 4th quarter valued at about $3,150,472,000. Morgan Stanley grew its position in Pfizer by 10.3% in the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after acquiring an additional 7,419,929 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 13.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after purchasing an additional 6,972,650 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Pfizer in the first quarter valued at approximately $311,238,000. 67.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction dated Monday, May 8th. The shares were acquired at an average cost of $38.58 per share, for a total transaction of $38,580.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at approximately $231,480. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.05% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent research reports. Jefferies Financial Group started coverage on shares of Pfizer in a research note on Monday, March 6th. They set a “hold” rating and a $43.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Pfizer in a research note on Wednesday, May 17th. JPMorgan Chase & Co. set a $45.00 target price on Pfizer in a report on Monday, February 27th. Wells Fargo & Company cut their price target on Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. Finally, UBS Group decreased their price objective on Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $47.33.

Pfizer Stock Down 1.1 %

Shares of NYSE:PFE opened at $38.30 on Monday. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31. The firm has a 50 day simple moving average of $38.71 and a 200-day simple moving average of $42.62. The company has a market capitalization of $216.22 billion, a PE ratio of 7.54, a P/E/G ratio of 1.27 and a beta of 0.64. Pfizer Inc. has a twelve month low of $36.17 and a twelve month high of $54.93.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. The firm had revenue of $18.28 billion during the quarter, compared to analysts’ expectations of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. Pfizer’s quarterly revenue was down 28.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.62 earnings per share. On average, equities analysts predict that Pfizer Inc. will post 3.35 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be given a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 4.28%. The ex-dividend date is Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is 32.28%.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.